COPN — Cosmo Pharmaceuticals NV Cashflow Statement

0.000.00%

Last trade - 00:00

HealthcareBalancedMid CapContrarian

Annual cashflow statement for Cosmo Pharmaceuticals NV, fiscal year end - December 31st, EUR millions except per share, conversion factor applied.

	2020 December 31st	2021 December 31st	2022 December 31st	C2023 December 31st	2024 December 31st
Period Length:	12 M	12 M	12 M	12 M	12 M
Source:	ARS	ARS	ARS	ARS	ARS
Standards:	IFRS	IFRS	IFRS	IFRS	IFRS
Status:	Final	Final	Final	Final	Final
Net Income/Starting Line	-6.93	24	24.5	-6.97	153
Depreciation
Non-Cash Items	16.1	-11.1	10.2	11.5	1.14
Unusual Items
Equity in Net Earnings/Losses
Other Non-Cash Items
Changes in Working Capital	-2.27	-7.7	-15.3	6.3	-4.38
Change in Accounts Receivable
Change in Inventories
Change in Other Assets
Change in Accounts Payable
Change in Other Liabilities
Net Change in Other Assets & Liabilities
Other Operating Cash Flow
Cash from Operating Activities	13	12.6	33.2	22.7	162
Capital Expenditures	-8.09	-8.5	-7.31	-4.4	-5.65
Purchase of Fixed Assets
Purchase / Acquisition of Intangibles
Other Investing Cash Flow Items	83.5	33.4	9	57.6	-123
Acquisition of Business
Sale of Business
Sale/Maturity of Investment
Purchase of Investments
Sale of Intangible Assets
Other Investing Cash Flow
Cash from Investing Activities	75.4	24.9	1.69	53.2	-129
Financing Cash Flow Items	-4.38	-4.88	-4.38	-6.38	-4.5
Other Financing Cash Flow
Total Cash Dividends Paid
Net Issuance / Retirement of Stock
Net Issuance / Retirement of Debt
Cash from Financing Activities	-11.9	-27.2	-46.1	-211	-40.2
Foreign Exchange Effects
Beginning Cash Balance
Ending Cash Balance
Net Change in Cash	75.5	12.6	-12.7	-136	-5.98